Basal Insulin for Type 2 Diabetes Patients Treated in Outpatient Clalit Clinics (Lapas II)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00726674|
Recruitment Status : Completed
First Posted : August 1, 2008
Last Update Posted : March 8, 2012
|Condition or disease|
|Type 2 Diabetes|
Patients with diabetes treated in outpatient clinics will be recruited by their primary care physician. Recruitment period will be 3 months per center and each patient will be followed for 7 months Diabetes specialists will be responsible for 50-65 primary care physicians. The specialists will advise and direct the primary care physician through the whole study period.
The study protocol includes patients treated with different types of non short- acting insulin. Insulin Lantus (including dose) will be started by the primary physician, if needed after consulting the Diabetes Specialist. The treatment should follow the study protocol.
Patients will have 3 pre-scheduled visits in their clinic: 1. At the beginning of study. 2. After 3 months. 3. At study end (after 6 month). An additional telephone contact will take place 1 month after last visit. to evaluate adherence to therapy Data collecting: Data including HbA1c, FPG,current diabetic treatment, dose of insulin Lantus, and relevant additional diseases\complaints will be collected at each visit. Additional information as demographic data, medical history will be collected at beginning of study.
Safety: Hypoglycaemic episodes will be recorded
|Study Type :||Observational|
|Actual Enrollment :||1229 participants|
|Official Title:||Lantus for Diabetic Patients Treated in Clalit Outpatient Clinics|
|Study Start Date :||August 2008|
|Actual Primary Completion Date :||January 2012|
|Actual Study Completion Date :||January 2012|
- Decrease in HbA1c level [ Time Frame: 6 months ]
- Safety measures [ Time Frame: 7 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00726674
|Sanofi-Aventis Administrative Office|
|Study Director:||Nurit Tweezer-Zaks||Sanofi|